Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GE HealthCare Technologies (GEHC) Research & Development (2022 - 2025)

GE HealthCare Technologies' Research & Development history spans 4 years, with the latest figure at $323.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 6.1% year-over-year to $323.0 million, compared with a TTM value of $1.3 billion through Dec 2025, down 3.81%, and an annual FY2025 reading of $1.3 billion, down 3.89% over the prior year.
  • Research & Development for Q4 2025 was $323.0 million at GE HealthCare Technologies, up from $292.0 million in the prior quarter.
  • The five-year high for Research & Development was $344.0 million in Q4 2024, with the low at $238.0 million in Q1 2022.
  • Average Research & Development over 4 years is $300.2 million, with a median of $308.5 million recorded in 2023.
  • Year-over-year, Research & Development rose 23.85% in 2023 and then dropped 7.65% in 2025.
  • Tracing GEHC's Research & Development over 4 years: stood at $271.0 million in 2022, then grew by 16.24% to $315.0 million in 2023, then grew by 9.21% to $344.0 million in 2024, then fell by 6.1% to $323.0 million in 2025.
  • Per Business Quant, the three most recent readings for GEHC's Research & Development are $323.0 million (Q4 2025), $292.0 million (Q3 2025), and $302.0 million (Q2 2025).